Patents
Percutaneous epicardial injection
Patent Number: 6659950As stem cell therapy advances, it becomes more and more important to develop methods of administering the stem cells. In this particular invention a medical device is provided that can inject stem cells, as well as growth factors and other cells, into the epicardium. This of course is useful for many cardiac conditions.
Inventor: Taheri, Syde (Buffalo, NY)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Friday March 2nd, 2001
High efficiency gene targeting in mouse embryonic stem cells
Patent Number: 6653113This patent teaches ways of generating knockout mice through targeting of the mouse embryonic stem cell with the various targeting constructs and approaches that are disclosed.
Inventors: Berns, Anton (Spaarndam, NL); Robanus Maandag, Els (Haarlem, NL); te Riele, Hein (Amsterdam, NL)
Assignee: Genpharm International, Inc. (Mountain View, CA)
Date of First Priority Issue: Tuesday August 20th, 1991
Human growth differentiation factor encoding sequence and polypeptide encoded by such DNA sequence and producing method thereof
Patent Number: 6656708This patent provides a novel protein that is capable of stimulating stem cell proliferation and differentiation. The protein is called human growth differentiation factor (hGDF3-2). This patent is useful for generation of novel stem cell activating therapeutics. Additionally, it may be used to generate competition to the currently used stem cell stimulatory cytokines.
Inventors: Yu, Long (Shanghai, CN); Zhang, Honglai (Shanghai, CN); Fu, Qiang (Shanghai, CN); Dai, Fangyan (Shanghai, CN); Zhao, Shouyuan (Shanghai, CN)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Tuesday September 22nd, 1998
Method of evaluating myelosuppressive state
Patent Number: 6649352After chemotherapy or radiation therapy, the myeloid compartment of the immune response is suppressed, due to destruction of the myeloid stem cell compartment. This patent provides a kit that allows the determination of myelosuppression, and therefore can be used to guide the amount of myelo-stimulatory therapy (ie G-CSF) that should be administered. The kit measures alone or in combination...
Inventors: Blumenthal, Rosalyn D. (Belleville, NJ); Lew, Walter (Caldwell, NJ); Juweid, Malik (Bloomfield, NJ); Alisauskas, Rita (Hopatcong, NJ); Ying, Zhiliang (East Brunswick, NJ); Goldenberg, David M. (Mendham, NJ)
Assignee: Center for Molecular Medicine and Immunology (Belleville, NJ)
Date of First Priority Issue: Friday January 29th, 1999
Isolated stromal cells for use in the treatment of diseases of the central nervous system
Patent Number: 6653134This patent teaches that one can induce the differentiation of stromal stem cells into neural cells, through the culture of the stromal cells with differentiated neural cells. This patent is useful not only for generating cells for treatment of neurological conditions, but also may be used to begin elucidating what the specific signals are that the neural cells use to teach the stromal stem cells...
Inventors: Prockop, Darwin J. (Philadelphia, PA); Stokes, David G. (Willow Grove, PA); Azizi, S. Ausim (Philadelphia, PA)
Assignee: CP Hahnemann University (Philadelphia, PA)
Date of First Priority Issue: Sunday March 28th, 1999
Cardiac valve replacement
Patent Number: 6652583This patent teaches how to use stem cells and other differentiated cells in order to generate a heart valve that can be used for replacement of defective valves in patients suffering from various valvular abnormalities. The advantage of this biological valve is that it conceptually is longer lasting than completely artificial or xenogeneic valves.
Inventors: Hopkins, Richard A. (Providence, RI); Hoffman-Kim, Diane (Providence, RI)
Assignee: Rhode Island Hospital (Providence, RI)
Date of First Priority Issue: Tuesday April 4th, 2000
Methods for use of delivery composition for expanding, activating, committing or mobilizing one or more pluripotent, self-renewing and committed stem cells
Patent Number: 6649189This patent covers a method of administering a hematopoeitic stem cell activatory factor into a host using a depot-like formulation. One of the problems of protien administration into humans is that many proteins have a short half live and therefore the pharmacokinetic profiles may not be adequate for stimulation of the biological response needed. This patent seems to overcome this problem.
Inventors: Talmadge, James E. (Bellevue, NE); Rosenthal, Gary J. (Louisville, CO); Etter, Jeffrey B. (Boulder, CO)
Assignee: RxKinetix, Inc. (Louisville, CO)
Date of First Priority Issue: Monday June 26th, 2000
Medicinal implant and device and method for loading and delivering implants containing drugs and cells
Patent Number: 6648849This patent covers a medical device that can be used for administering stem cells together with various polymers and depot-like formulations into a host. The administration of stem cells together with growth factors is useful since this can allow the stem cells to remain in an "activated" state and accelerate their process of interacting with the host cells.
Inventors: Tenhuisen, Kevor S. (Clinton, NJ); Rosenblatt, Joel (Watchung, NJ); McAllen, III, John (Point Pleasant, NJ)
Assignee: Ethicon, Inc. (Somerville, NJ)
Date of First Priority Issue: Wednesday June 27th, 2001
Immortalized bone marrow mesenchymal stem cell
Patent Number: 6645763This patent has one claim that covers a specific mesenchymal stem cell population that is immortalized and appears to contain a gene associated with immortalization.
Inventors: Kobayashi, Naoya (Okayama 703-8261, JP); Leboulch, Philippe (Charlestown, MA); Tanaka, Noriaki (Okayama 719-0252, JP); Fujiwara, Toshiyoshi (Okayama 703-8281, JP)
Assignee: Unknown Assignee(s)
Date of First Priority Issue: Monday November 12th, 2001
Antibody compositions for preparing enriched mesenchymal progenitor preparations
Patent Number: 6645727This patent covers the antibody kit that can be used for negatively depleting non-mesenchymal stem cell populations from a population of cells in order to obtain a substantially purified population of mesenchymal stem cells.
Inventors: Thomas, Terry (Vancouver, CA); Clarke, Emer (Vancouver, CA)
Assignee: StemCell Technologies Inc. (Vancouver, CA)
Date of First Priority Issue: Friday May 26th, 2000